Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

“SENOLYTIC” DRUG REVERSES KEY CAUSE OF AGING

As the human body ages, it accumulates a growing number of “senescent” cells that lose their ability to work properly or even go dormant. As more of these cells build up, the symptoms of ageing become more pronounced – everything from dementia to crepe-like skin.
“Senolytic” drugs that could clear away senescent cells have been in the lab for some time. But now scientists at the Mayo Clinic have shown for the first time that a senolytic drug actually can sweep senescent cells out of the human body without creating collateral damage.
Nine people with diabetic kidney disease were given three daily doses of dasatinab, one of the Mayo Clinic’s senolytics, combined with quercitin, a plant pigment known to reduce inflammation and scavenge free radicals from the body.
Although the drug doses cleared out of the body within 48 hours, senescent cells continued to flush from kidney tissue for at least 11 days.
TRENDPOST: Senolytic drugs will draw an increasing focus of research attention and dollars as demand grows for therapies that manage and forestall the processes of aging. By 2030, senolytics will be a routine part of physicians’ anti-aging therapy portfolio.

Comments are closed.